Chandra Vargeese - 05 Feb 2026 Form 4 Insider Report for Wave Life Sciences Ltd. (WVE)

Role
Chief Technology Officer, Head of Platform Discovery Sciences
Signature
/s/ Chandra Vargeese
Issuer symbol
WVE
Transactions as of
05 Feb 2026
Net transactions value
-$43,417
Form type
4
Filing time
11 Feb 2026, 21:00:05 UTC
Previous filing
05 Mar 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Vargeese Chandra Chief Technology Officer, Head of Platform Discovery Sciences C/O WAVE LIFE SCIENCES LTD.,, 733 CONCORD AVE., CAMBRIDGE /s/ Chandra Vargeese 11 Feb 2026 0001657675

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WVE Ordinary Shares Award $0 +45,625 +12% $0.000000 411,474 05 Feb 2026 Direct F1, F2
transaction WVE Ordinary Shares Sale $43,417 -3,228 -0.78% $13.45 408,246 09 Feb 2026 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WVE Share Option (right to buy) Award $0 +273,750 $0.000000 273,750 05 Feb 2026 Ordinary Shares 273,750 $12.75 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030.
F2 Includes 3,162 ordinary shares acquired on July 15, 2025, and January 14, 2026, under the issuer's 2019 Employee Share Purchase Plan.
F3 On February 9, 2026, the reporting person sold 3,228 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.
F4 The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030.

Remarks:

Chief Technology Officer, Head of Platform Discovery Sciences